In pre-clinical murine studies, ex vivo expanded human UCB CD4+CD25+ Tregs can prevent allogeneic GvHD, reduce Il-17 production, and tip the Treg/Th17 balance in favor of Tregs (152). Here, IL2RA is linked to graft versus host disease.